• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    GH Research PLC - Ordinary Shares (NQ:GHRS)

    27.42 -0.33 (-1.19%)
    Streaming Delayed Price Updated: 12:35 PM EDT, Jul 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about GH Research PLC - Ordinary Shares

    < Previous 1 2 Next >
    News headline image
    Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
    EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:DFTX),(NASDAQ:CMPS),(NASDAQ:GHRS),(NYSE:JNJ) EQNX::TICKER_END 
    Via FinancialNewsMedia
    News headline image
    Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
    Next-generation MDD drugs are driving a new era of innovation, investment, and commercial opportunity 
    From MarketNewsUpdates.com
    Via GlobeNewswire
    News headline image
    GH Research Announces Publication of Phase 2a Postpartum Depression Results
    From GH Research PLC
    Via GlobeNewswire
    News headline image
    GH Research Reports First Quarter 2026 Financial Results and Provides Business Update
    From GH Research PLC
    Via GlobeNewswire
    News headline image
    GH Research Announces Pricing of $117.5 Million Underwritten Offering
    From GH Research PLC
    Via GlobeNewswire
    News headline image
    GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness
    From GH Research PLC
    Via GlobeNewswire
    News headline image
    GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD
    From GH Research PLC
    Via GlobeNewswire
    News headline image
    GH Research Reports Full Year 2025 Financial Results and Provides Business Update
    From GH Research PLC
    Via GlobeNewswire
    News headline image
    GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026
    From GH Research PLC
    Via GlobeNewswire
    News headline image
    GH Research to Announce IND Status for GH001
    From GH Research PLC
    Via GlobeNewswire
    News headline image
    GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates
    From GH Research PLC
    Via GlobeNewswire
    News headline image
    GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress
    From GH Research PLC
    Via GlobeNewswire
    News headline image
    GH Research Reports Second Quarter 2025 Financial Results and Provides Business Updates
    From GH Research PLC
    Via GlobeNewswire
    News headline image
    GH Research Announces Global Pivotal Program Plans and Further Development Updates
    From GH Research PLC
    Via GlobeNewswire
    News headline image
    GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule
    From GH Research PLC
    Via GlobeNewswire
    News headline image
    GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting
    From GH Research PLC
    Via GlobeNewswire
    News headline image
    GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates
    From GH Research PLC
    Via GlobeNewswire
    News headline image
    GH Research Reports Full Year 2024 Financial Results and Provides Business Updates
    From GH Research PLC
    Via GlobeNewswire
    News headline image
    GH Research Announces Pricing of $150 Million Public Offering
    From GH Research PLC
    Via GlobeNewswire
    News headline image
    GH Research Announces Proposed Public Offering
    From GH Research PLC
    Via GlobeNewswire
    News headline image
    GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction
    From GH Research PLC
    Via GlobeNewswire
    News headline image
    GH Research to Provide Update on Phase 2b Trial with GH001 in TRD
    From GH Research PLC
    Via GlobeNewswire
    News headline image
    GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents
    From GH Research PLC
    Via GlobeNewswire
    News headline image
    GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates
    From GH Research PLC
    Via GlobeNewswire
    News headline image
    GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates
    From GH Research PLC
    Via GlobeNewswire
    News headline image
    GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer
    From GH Research PLC
    Via GlobeNewswire
    News headline image
    GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates
    From GH Research PLC
    Via GlobeNewswire
    News headline image
    GH Research Reports Full Year 2023 Financial Results and Provides Business Updates
    From GH Research PLC
    Via GlobeNewswire
    News headline image
    GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression
    From GH Research PLC
    Via GlobeNewswire
    News headline image
    GH Research Reports Third Quarter Financial Results and Provides Business Updates
    From GH Research PLC
    Via GlobeNewswire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.